Athira Pharma Inc (ATHA): Price-to-Sales Ratio

Corporate company logo of Athira (ATHA)

The success of Athira Pharma, Inc. (ATHA) therapy depends on strict adherence to temperature controls during protein transportation. Patents for Fosgonimeton and rigorous FDA oversight create a high barrier to entry. Expected small molecule tests will serve as new growth triggers. The shift in the P/S multiple reflects the market valuation, with the indicator currently at .

ATHA: Athira Pharma, Inc. P/S Multiple 07/04/2022 - 11/14/2026

Metric breakdowns and analytics for athira.com (ATHA)

- share price and consensus valuation forecast:
Price Performance Chart Athira Pharma Inc|ATHA - Price Target Chart
- stock exchange capitalization data:
Market Valuation Athira Pharma Corp|ATHA - Enterprise Value
- balance sheet net asset value indicators:
Accounting Value of a Share Athira Pharma|ATHA - Book Capitalization|Market Capitalization to Book Value Ratio athira.com|ATHA - Aggregate Company Assets
- debt obligations and liquidity statistics:
All Debt to Shareholders' Equity Ratio Athira Pharma, Inc.|ATHA - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Athira Pharma, Inc.|ATHA - Company Aggregate Debts|Debts to Book Capitalization Athira Pharma, Inc.|ATHA - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Athira Pharma|Interim Coverage Ratio athira.com
- earnings and valuation multiples information:
ATHA - Company Net Income|Net Profit Forecast Athira Pharma, Inc.|ATHA - P/E Multiple|Projected Price to Earnings Athira Pharma, Inc.|ATHA - Price/Earnings to Growth Multiple|Total Company Value to Operating Income Before Depreciation Ratio Athira Pharma Corp|ATHA - Operating profit EBITDA|Net earnings per share (EPS TTM) Athira Pharma|ATHA - Net earnings per share for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months athira.com|ATHA - Earnings growth in current year|Expected earnings per share trend next year Athira Pharma, Inc.
- issuer revenue and sales details:
ATHA - Revenue and Sales Volume|Projected Sales Volume Athira Pharma Inc|ATHA - Price-to-Revenue Ratio|Market Cap to Projected Revenue Athira Pharma Corp
General company analysis:ATHA Athira
Finished products of Athira Pharma, Inc.

To select high-quality assets, an investor must compare the market value of a business with its actual ability to generate income. The P/S multiple is calculated as the ratio of market capitalization to annual revenue, determining the market's valuation of each dollar of sales. For Athira Pharma, Inc. (ATHA), this metric reflects expectations regarding the commercialization of Alzheimer's disease treatments. By analyzing the capitalization-to-revenue ratio, one can assess the extent to which the stock is overbought relative to its current cash flows.

Who Athira Pharma, Inc. competes with

BIIB (Biogen) - Market Capitalization-to-Revenue Ratio|P/S Multiple NBIX (Neurocrine Corp)|Regencell Bioscience - Price-to-Revenue Ratio|Axsome Therapeutics - P/S Multiple|Market Capitalization-to-Revenue Ratio ACAD (ACADIA Pharmaceuticals)|Xenon (XENE) - Price-to-Revenue Ratio|Price to Sales Viking Therapeutics Inc (VKTX)|SUPN (Supernus Pharma) - P/S Multiple|CPRX: Market Capitalization-to-Revenue Ratio|P/S Multiple DNLI|Price-to-Revenue Coefficient Harmony Biosciences|Biohaven Ltd - Market Cap to Revenue|P/S Multiple Amylyx Pharmaceuticals, Inc. AMLX|TRVI: Market Cap to Revenue|Price-to-Revenue Coefficient Praxis Corp PRAX|AVXL: P/S Multiple|CBLL (ceribell.com) - Price-to-Revenue Ratio|PRTA (Prothena Corporation) - P/S Multiple|Market Cap to Revenue alector.com (ALEC)|Price-to-Revenue Ratio Annexon, Inc. (ANNX)|OMER - Price to Sales|P/S Multiple NGNE (Neurogene Inc)|AC Immune (ACIU) - Price to Sales|Voyager Therapeutics Inc - P/S Multiple|Neumora (NMRA) - Market Cap to Revenue|SCLX: P/S Multiple|TVGN - Price-to-Revenue Coefficient|ACOG (Alpha Cognition Inc) - P/S Multiple|Market Cap to Revenue cogrx.com (CGTX)|Price-to-Revenue Ratio Inhibikase Therapeutics Inc (IKT)|Price-to-Revenue Coefficient Cassava Sciences|P/S Multiple ASRT (Assertio Holdings)|COYA - Market Cap to Revenue|vistagen.com - P/S Multiple|OVID: Price-to-Revenue Ratio|Acumen Pharmaceuticals, Inc (ABOS) - Price-to-Revenue Ratio|CervoMed Inc - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Alterity Therapeutics Limited|clene.com (CLNN) - Price-to-Revenue Coefficient|Market Cap to Revenue PEPG (PepGen Inc)|P/S Multiple jupiterneurosciences.com (JUNS)|Price-to-Revenue Ratio Relmada Therapeutics, Inc. RLMD|ANVS: Market Cap to Revenue Ratio|Grace Tx - P/S Multiple|AIFF (Firefly Neuroscience Inc) - Market Cap to Revenue Ratio|KLTO: P/S Multiple|NeuroSense Therapeutics, Ltd. (NRSN) - P/S Multiple|Price-to-Revenue Ratio Reviva Pharmaceuticals, Inc.|Market Cap to Revenue metaviatx.com (MTVA)|P/S Multiple NRXS|HSDT - Price to Sales|Passage Bio, Inc. - Market Cap to Revenue|bionomics.com.au (NEUP) - Price to Sales|Minerva - P/S Multiple|Addex Therapeutics Ltd - Market Cap to Sales Volume|Alzamend Neuro, Inc. (ALZN) - Price-to-Revenue Ratio|CYCN (Cyclerion Therapeutics Inc.) - Price-to-Revenue Ratio|Market Cap to Revenue PTIX|KTTA: Market Capitalization-to-Revenue Ratio|Market Cap to Revenue CRGT (Cortigent Medical)|ATXI (Avenue Therapeutics, Inc.) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Brainstorm Cell Therapeutics, Inc. BCLI|Market Capitalization-to-Revenue Ratio CARA|chromocell.com - P/S Multiple|Price-to-Sales Ratio ELYM|ITCI: P/S Multiple|Price to Sales Longboard Pharmaceuticals, Inc. (LBPH)|Price-to-Revenue Ratio Marinus Pharmaceuticals, Inc.|NKGN: Market Capitalization-to-Revenue Ratio|P/S Multiple NRBO|SAGE: Price-to-Sales Ratio|Synaptogenix Inc. - Market Cap to Revenue|Market Cap to Sales Volume TRVN (Trevena Inc.)|Vigil Neuroscience, Inc. - P/S Multiple|Anew Medical (WENA) - Market Cap to Revenue|CERE (Cerevel Corp) - Market Cap to Revenue